We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

31 hedge funds and large institutions have $12M invested in Lisata Therapeutics in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

811% more call options, than puts

Call options by funds: $82K | Put options by funds: $9K

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

154% more capital invested

Capital invested by funds: $4.71M → $12M (+$7.27M)

55% more funds holding

Funds holding: 20 → 31 (+11)

Holders
31
Holders Change
+11
Holders Change %
+55%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
7
Reduced
1
Closed
7
Calls
$82K
Puts
$9K
Net Calls
+$73K
Net Calls Change
+$73K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$970K
2
SC
Sophrosyne Capital
New York
+$526K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$500K
4
OAM
Oxford Asset Management
United Kingdom
+$474K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$412K

Top Sellers

Rank Fund Capital Flow
1
LOM
Loeb Offshore Management
New York
-$83K
2
FHC
First Heartland Consultants
Missouri
-$56K
3
Neuberger Berman Group
Neuberger Berman Group
New York
-$38K
4
GC
Guggenheim Capital
Illinois
-$29K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.9M +$35.5K +32 +1%
PA
2
Perceptive Advisors
New York
$2.83M – – –
Morgan Stanley
3
Morgan Stanley
New York
$1.23M +$970K +874 +993%
SC
4
Sophrosyne Capital
New York
$607K +$526K +474 New
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$577K +$500K +450 New
OAM
6
Oxford Asset Management
United Kingdom
$547K +$474K +427 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$531K +$23.3K +21 +5%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$475K +$412K +371 New
DC
9
Deere & Company
Illinois
$412K +$356K +321 New
AQR Capital Management
10
AQR Capital Management
Connecticut
$332K +$288K +259 New
Northern Trust
11
Northern Trust
Illinois
$294K +$113K +102 +80%
Renaissance Technologies
12
Renaissance Technologies
New York
$257K +$222K +200 New
Bank of America
13
Bank of America
North Carolina
$111K +$37.8K +34 +64%
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$106K – – –
CS
15
Credit Suisse
Switzerland
$105K +$91.1K +82 New
State Street
16
State Street
Massachusetts
$104K – – –
PP
17
Paloma Partners
Connecticut
$94K +$81.1K +73 New
VKH
18
Virtu KCG Holdings
New York
$93K +$81.1K +73 New
Nomura Holdings
19
Nomura Holdings
Japan
$90K +$8.88K +8 +13%
Barclays
20
Barclays
United Kingdom
$88K +$81.1K +73 New
U
21
UBS
Switzerland
$70K +$56.6K +51 +1,275%
Deutsche Bank
22
Deutsche Bank
Germany
$35K +$30K +27 New
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$32K -$1.11K -1 -4%
BIT
24
BlackRock Institutional Trust
California
$26K +$22.2K +20 New
PCM
25
Prelude Capital Management
New York
$15K +$13.3K +12 New
1
2

LSTA Hedge Fund Activity: Q3 2013 in Review

31 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2013, worth a combined $12M — up 154% from $4.71M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new LSTA positions and 7 closed out — a net gain of 11 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $970K. The largest seller was Loeb Offshore Management, exiting entirely with an estimated $83K sold.

  • 31 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2013, up from 20 in Q2 2013.
  • Funds reported $12M of Lisata Therapeutics stock for Q3 2013, up 154% quarter-over-quarter.
  • 18 funds opened new Lisata Therapeutics positions in Q3 2013 and 7 closed out, a net change of +11 holders.
  • The largest Lisata Therapeutics buyer in Q3 2013 was Morgan Stanley, an estimated $970K added.
  • The largest Lisata Therapeutics seller in Q3 2013 was Loeb Offshore Management, an estimated $83K sold.

Based on aggregated 13F filings for Q3 2013.